MX2018006986A - Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. - Google Patents

Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Info

Publication number
MX2018006986A
MX2018006986A MX2018006986A MX2018006986A MX2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A
Authority
MX
Mexico
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
treat osteoarthritis
osteoarthritis
Prior art date
Application number
MX2018006986A
Other languages
English (en)
Spanish (es)
Inventor
K Pinkstaff Jason
A O'neill Charles
M Oppeneer Todd
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018006986A publication Critical patent/MX2018006986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2018006986A 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. MX2018006986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
MX2018006986A true MX2018006986A (es) 2018-09-05

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006986A MX2018006986A (es) 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Country Status (17)

Country Link
US (2) US11202819B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019038A3 (cg-RX-API-DMAC7.html)
JP (1) JP7104625B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180088459A (cg-RX-API-DMAC7.html)
CN (1) CN108697766A (cg-RX-API-DMAC7.html)
AU (2) AU2016365751B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007315A1 (cg-RX-API-DMAC7.html)
DK (1) DK3386531T3 (cg-RX-API-DMAC7.html)
ES (1) ES2901769T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211908T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057083T2 (cg-RX-API-DMAC7.html)
IL (1) IL259690B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018006986A (cg-RX-API-DMAC7.html)
PL (1) PL3386531T3 (cg-RX-API-DMAC7.html)
PT (1) PT3386531T (cg-RX-API-DMAC7.html)
RU (1) RU2759679C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017100400A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
IL318754A (en) 2016-01-08 2025-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
MY195190A (en) 2016-01-08 2023-01-11 Ascendis Pharma Growth Disorders As Controlled-Release Cnp Agonists With Increased Nep Stability
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
LT3518930T (lt) 2016-09-29 2023-05-10 Ascendis Pharma Growth Disorders A/S Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais
US20210228497A1 (en) * 2018-04-27 2021-07-29 Remy Biosciences, Inc. New Medical Devices, Delivery Vehicles and Manufacturing Thereof
KR102893903B1 (ko) * 2019-02-11 2025-12-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
EP4337957A1 (en) * 2021-05-11 2024-03-20 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
AU2022407450A1 (en) * 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
JP2025521254A (ja) 2022-11-02 2025-07-08 ノヴォ ノルディスク アー／エス Ｃｎｐ化合物
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2561530C (en) 2004-03-31 2014-04-22 Kazuwa Nakao Therapeutic or prophylactic agent for arthritis
EP3446711A1 (en) * 2004-03-31 2019-02-27 Kazuwa Nakao Composition for increasing body height
CA2705603A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
EP4029512A1 (en) * 2009-05-20 2022-07-20 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
PL3386531T3 (pl) 2022-02-28
PT3386531T (pt) 2021-12-29
RU2018124600A (ru) 2020-01-13
EP4019038A2 (en) 2022-06-29
CA3007315A1 (en) 2017-06-15
US20220160836A1 (en) 2022-05-26
EP3386531B1 (en) 2021-10-13
IL259690B (en) 2022-10-01
IL259690A (en) 2018-07-31
RU2021132347A (ru) 2022-03-24
CN108697766A (zh) 2018-10-23
WO2017100400A3 (en) 2017-10-26
DK3386531T3 (da) 2022-01-03
RU2759679C2 (ru) 2021-11-16
EP4019038A3 (en) 2022-09-28
US20190247467A1 (en) 2019-08-15
EP3386531A2 (en) 2018-10-17
HRP20211908T1 (hr) 2022-03-04
JP7104625B2 (ja) 2022-07-21
RU2018124600A3 (cg-RX-API-DMAC7.html) 2020-01-13
US12214015B2 (en) 2025-02-04
AU2024201852A1 (en) 2024-04-11
HUE057083T2 (hu) 2022-04-28
KR20180088459A (ko) 2018-08-03
AU2016365751A1 (en) 2018-06-21
IL259690B2 (en) 2023-02-01
US11202819B2 (en) 2021-12-21
WO2017100400A2 (en) 2017-06-15
AU2016365751B2 (en) 2023-12-21
ES2901769T3 (es) 2022-03-23
JP2019505486A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2018006986A (es) Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12017502180A1 (en) Tau-binding antibodies
ZA201803366B (en) Antibody molecules to april and uses thereof
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MX2022003184A (es) Variantes del cnp y sus conjugados.
MY208384A (en) Pth prodrugs
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12017502207B1 (en) Tau-binding antibodies
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12017501864A1 (en) Compositions and methods for treating autism
AU363512S (en) Riser
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2020003551A (es) Metodos de tratamiento de dolor agudo o cronico.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MX2017006488A (es) Sistema de encuadernacion doble.
HK1262398A1 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
GB201707280D0 (en) Mediated per to peer transaction systems and methods
UA104214U (ru) Применение метода определения диастолической дисфункции сердца как способа определения порога толерантности к физическим нагрузкам
AU365764S (en) Wire balustrade connection fitting